Humoral Immune Response to SARS-CoV-2 Vaccination

In response to vaccination against SARS-CoV-2, the humoral immune system mounts a coordinated reaction characterised by the production of antigen-specific antibodies, primarily of the IgG isotype, directed against the viral spike protein. Following initial priming with two doses of mRNA or vector-based vaccines, antibody levels peak within weeks and are accompanied by the formation of germinal centres that drive affinity maturation. Over subsequent months, circulating antibody titres decline, yet a pool of memory B cells develops, poised to rapidly re-expand upon antigen re-exposure. Booster doses reinvigorate waning immunity, leading to greater neutralising breadth against emerging variants and enhancing the potency of memory B cell repertoires. Hybrid immunity, resulting from a combination of natural infection and vaccination, typically yields higher antibody titres and a more diverse memory B cell population, with improved mucosal targeting and functional resilience against immune escape. These insights underpin ongoing vaccination strategies aimed at sustaining global protection and reducing severe disease.

Research from Nature Portfolio

Recent studies have systematically explored how distinct antigen exposures shape B cell and antibody responses. Individuals receiving two mRNA vaccine doses followed by breakthrough infection with Delta or Omicron variants display markedly enhanced neutralising activity, with plasma neutralisation titres against Omicron rising up to forty-fold compared to two-dose vaccination alone. A third mRNA booster further amplifies spike-specific memory B cell frequencies and drives the emergence of new clones targeting conserved regions of the receptor-binding domain; more than 50% of memory antibodies after the booster neutralise Omicron. Analyses across varied exposure scenarios confirm that hybrid immunity—combining vaccination and breakthrough infection—elicits superior protective correlates, featuring robust B cell clonality, high-affinity antibodies and coordinated T helper cell support that outperform responses induced by vaccination or infection in isolation.

Humoral Immune Response to SARS-CoV-2 Vaccination publication trend

The graph below shows the total number of articles in humoral immune response to sars-cov-2 vaccination across all publications each year (not limited to Nature Index journals).

Technical terms

Neutralising antibody: an antibody that binds to viral surface proteins and prevents viral entry into host cells.

Memory B cell: a long-lived B lymphocyte that, upon re-encounter with its specific antigen, rapidly differentiates into antibody-secreting cells.

Antigenic breadth: the range of viral variants or epitopes recognised by antibodies or B cell receptors.

Booster: an additional vaccine dose administered after the primary series to restore or enhance immune protection.

References

1. B-cell and antibody responses to SARS-CoV-2: infection, vaccination, and hybrid immunity. Cellular & Molecular Immunology (2023).
2. SARS-CoV-2 humoral and cellular immunity following different combinations of vaccination and breakthrough infection. Nature Communications (2023).
3. Prior SARS-CoV-2 infection enhances and reshapes spike protein–specific memory induced by vaccination. Science Translational Medicine (2023).
4. Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost. Nature (2022).